<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01662882</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-J05</org_study_id>
    <secondary_id>I6E-AV-AVBB</secondary_id>
    <nct_id>NCT01662882</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)</brief_title>
  <official_title>An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <brief_summary>
    <textblock>
      Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing
      Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or
      Mild cognitive impairment (MCI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative Amyloid Image Assessment</measure>
    <time_frame>50-60 min after injection</time_frame>
    <description>Five readers blinded to all clinical information classified florbetapir-Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read was the primary efficacy endpoint for the qualitative evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Cortical to Cerebellum SUVR</measure>
    <time_frame>50-60 min after injection</time_frame>
    <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>AD Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MCI (mild cognitive impairment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir (18F)</intervention_name>
    <description>IV injection, 370 MBq(10mCi), single dose</description>
    <arm_group_label>AD Subjects</arm_group_label>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>18F-AV-45</other_name>
    <other_name>Amyvid</other_name>
    <other_name>Florbetapir F 18</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who meet all of the following criteria are eligible to enroll in the arm of this
        trial reserved for subjects with AD:

          1. Japanese males or females at least 50 years of age, with probable AD according to the
             NINCDS-ADRDA criteria (McKhann et al., 1984);

          2. Subjects with mild/moderate dementia as evidenced by a MMSE score ranging from 10 to
             24, boundaries included, at screening;

          3. Subjects whose history of cognitive decline has been gradual in onset and progressive
             over a period of at least 6 months. Evidence should be present indicating sustained
             memory deterioration in an otherwise cognitively normal subject, plus additional
             impairment in another cognitive function such as: orientation, judgment and problem
             solving, or functioning in personal care;

          4. Subjects who live with or have regular visits from a responsible caregiver willing to
             provide information about the subject's cognitive status; and

          5. Subjects who signed an Institutional Review Board/Independent Ethics Committee
             (IRB/IEC) approved informed consent prior to any study procedures. If the subject is
             incapable of giving informed consent, the caregiver may consent on behalf of the
             subject (the subject must still confirm assent).

        Subjects who meet all of the following criteria are eligible to enroll in the arm of this
        trial reserved for subjects with mild cognitive impairment:

          1. Japanese males or females at least 50 years of age;

          2. Subjects with complaint of memory or cognitive decline corroborated by an informant;

          3. Subjects with a Clinical Dementia Rating (CDR) of 0.5;

          4. Subjects with objective cognitive impairment or marginally normal cognition with a
             documented history of high cognitive performance;

          5. Have no obvious causes for their cognitive impairment (e.g., onset coincides with
             recent head trauma or stroke);

          6. Have sufficiently preserved general cognition and functional performance such that a
             diagnosis of AD cannot be made at the time of the screening visit;

          7. Subjects with essentially normal ADL;

          8. Subjects who are not demented;

          9. Subjects with an MMSE score &gt; 24;

         10. Subjects who are presenting for initial diagnosis of cognitive impairment or who have
             presented for initial diagnosis of cognitive impairment within the past year;

         11. Subjects who live with or have regular visits from a responsible caregiver willing to
             provide information about the subject's cognitive status; and

         12. Subjects who signed an IRB/IEC approved informed consent prior to any study
             procedures.

        Subjects who meet all of the following criteria are eligible to enroll in the arm of this
        trial reserved for cognitively normal volunteers:

          1. Japanese males or females at least 50 years of age;

          2. Subjects with an MMSE score &gt;= 29, and are cognitively normal based on history and
             psychometric test battery at screening;

          3. Subjects who live with or have a reliable person who can verify their cognitive
             status; and

          4. Subjects who signed an IRB/IEC approved informed consent prior to any study
             procedures.

        Exclusion Criteria:

        Subjects with any of the following are ineligible to enroll in this trial:

          1. A documented diagnosis of MCI for greater than 1 year (for subjects considered for the
             MCI group);

          2. Neurodegenerative disorders other than AD, including, but not limited to Parkinson's
             disease, Pick's disease, frontotemporal dementia, Huntington's chorea, Down's
             syndrome, Creutzfeldt-Jacob disease, normal pressure hydrocephalus, and progressive
             supranuclear palsy;

          3. Have had or currently have a diagnosis of other dementing / neurodegenerative disease
             (e.g. Parkinson's disease, dementia with Lewy bodies, Lewy body variant AD, etc.);

          4. Have had or currently have a diagnosis of mixed dementia;

          5. Cognitive impairment resulting from:

               -  Acute cerebral trauma or post-traumatic brain injury, subdural hematoma, or
                  injuries secondary to chronic trauma (e.g. sequela from boxing);

               -  Hypoxic cerebral damage regardless of etiology; e.g. cognitive or neurological
                  deficits resulting from cardiac arrest or cardiac surgery, anesthesia, or severe
                  self-poisoning episode, secondary to severe hypovolemia (orthostatic hypotension
                  should not lead to exclusion);

               -  Vitamin deficiency states documented by medical history such as folate, vitamin B
                  12 and other B complex deficiencies; e.g. thiamin deficiency in Korsakoff's
                  syndrome. (Note: subjects taking regular B12 and folate are not necessarily
                  excluded);

               -  Cerebral infection including abscess, syphilis, meningitis, encephalitis or AIDS;

               -  Primary or metastatic cerebral neoplasia;

               -  Significant endocrine or metabolic disease; e.g., thyroid, parathyroid, or
                  pituitary disease, Cushing's syndrome, or severe renal failure; or

               -  Mental retardation. Before enrolling a subject with past or current history of
                  any of the above conditions, the investigator must contact the sponsor to discuss
                  whether the condition could have contributed to the cognitive impairment.

          6. Clinically significant infarct or possible multi-infarct dementia as defined by the
             NINCDS criteria, including:

               -  A history of a significant cerebrovascular event resulting in a physical or
                  neurologic deficit that may confound the assessment of the subject's intellectual
                  function;

               -  Multiple focal signs on neurologic examination indicative of multiple ischemic
                  episodes;

               -  One or more of the following findings on a MRI scan:

                    -  Multiple (two or more) infarcts or white matter lacunes;

                    -  A single large infarct or a strategically placed infarct in the angular
                       gyrus, the thalamus, the basal forebrain, the posterior cerebral artery
                       (PCA) or anterior cerebral artery (ACA) territory;

               -  Extensive periventricular white matter disease. Leukoaraiosis (periventricular
                  white matter, low attenuation) should be distinguished from multiple infarctions.
                  Leukoaraiosis is common in normal individuals and patients with AD. White matter
                  deterioration should not result in exclusion unless it is abnormal and
                  widespread, e.g., Binswanger's disease;

          7. Any evidence on screening MRI, computed tomography (CT), or other biomarker studies
             that suggests an alternate etiology (other than probable AD in subjects with AD) for
             cognitive deficit; or in the case of cognitively normal controls any evidence on
             screening MRI, CT, or other biomarker studies that suggests the presence of AD
             pathology;

          8. Current clinically significant psychiatric disease, as judged by Diagnostic and
             Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, particularly
             current major depression or schizophrenia. Subjects with dementia who are experiencing
             behavioral disturbances that may require treatment with psychotropic medications may
             be entered only after discussion and with the approval of the sponsor. The
             investigator and sponsor should carefully consider whether subjects with behavioral
             dysfunction will be able to complete the imaging session;

          9. History of epilepsy or convulsions, except for febrile convulsions during childhood;

         10. Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine
             disturbances;

         11. Current clinically significant cardiovascular disease. Clinically significant
             cardiovascular disease usually includes one or more of the following:

               -  cardiac surgery or myocardial infarction within the last 6 months;

               -  unstable angina;

               -  coronary artery disease that required an increase in medication within the last 3
                  months;

               -  decompensated congestive heart failure;

               -  significant cardiac arrhythmia or conduction disturbance, particularly those
                  resulting in atrial or ventricular fibrillation, or causing syncope, near
                  syncope, or other alterations in mental status;

               -  severe mitral or aortic valvular disease;

               -  uncontrolled high blood pressure;

               -  congenital heart disease;

               -  clinically significant abnormal result on ECG, including but not limited to QTc &gt;
                  450 msec. Before enrolling a subject with any of the above conditions, the
                  investigator must contact the sponsor.

         12. History of drug or alcohol abuse within the last year, or prior prolonged history of
             abuse;

         13. Clinically significant infectious disease, including Acquired Immune Deficiency
             Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) infection or previous positive
             test for hepatitis;

         14. Females of childbearing potential who are not surgically sterile, not refraining from
             sexual activity or not using reliable methods of contraception. Females of
             childbearing potential must not be pregnant (negative serum beta-hCG at the time of
             screening and negative urine beta-hCG on the day of imaging) or breastfeeding at
             screening. Females must agree to avoid becoming pregnant, and must agree to refrain
             from sexual activity or to use reliable contraceptive methods such as prescribed birth
             control or IUD for 24 hours following administration of florbetapir (18F);

         15. Subjects who, in the opinion of the investigator, are otherwise unsuitable for a study
             of this type;

         16. History of relevant severe drug allergy or hypersensitivity;

         17. Subjects who have received an investigational medication within the last 30 days.

             Additionally, the time between the last dose of the previous experimental medication
             and enrollment (completion of screening assessments) must be at least equal to 5 times
             the terminal half-life of the previous experimental medication. Subjects who have ever
             participated in an experimental study with an amyloid targeting therapy (e.g.,
             immunotherapy, secretase inhibitor) may not be enrolled unless it can be demonstrated
             that the subject received only placebo in the course of the trial;

         18. Subjects with current clinically significant medical comorbidities, as indicated by
             history, physical exam, ECG (including but not limited to QTc&gt;450 msec) or laboratory
             evaluations, that might pose a potential safety risk, interfere with the absorption or
             metabolism of the study medication or limit interpretation of the trial results. These
             include but are not limited to clinically significant hepatic, renal, pulmonary,
             metabolic or endocrine disease, cancer, HIV infection and AIDS;

         19. Subjects who have known hypersensitivity to alcohol; and

         20. Subjects who received a radiopharmaceutical for imaging or therapy within the past 7
             days prior to the imaging session for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2012</study_first_submitted>
  <study_first_submitted_qc>August 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2012</study_first_posted>
  <results_first_submitted>July 16, 2013</results_first_submitted>
  <results_first_submitted_qc>July 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2013</results_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AD Subjects</title>
          <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
        <group group_id="P3">
          <title>MCI Subjects</title>
          <description>MCI (mild cognitive impairment)
florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AD Subjects</title>
          <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
        <group group_id="B3">
          <title>MCI Subjects</title>
          <description>MCI (mild cognitive impairment)
florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="7.80"/>
                    <measurement group_id="B2" value="70.0" spread="11.15"/>
                    <measurement group_id="B3" value="73.3" spread="5.09"/>
                    <measurement group_id="B4" value="72.1" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Qualitative Amyloid Image Assessment</title>
        <description>Five readers blinded to all clinical information classified florbetapir-Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read was the primary efficacy endpoint for the qualitative evaluation.</description>
        <time_frame>50-60 min after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AD Subjects</title>
            <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
          </group>
          <group group_id="O2">
            <title>MCI Subjects</title>
            <description>MCI (mild cognitive impairment)
florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Qualitative Amyloid Image Assessment</title>
          <description>Five readers blinded to all clinical information classified florbetapir-Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read was the primary efficacy endpoint for the qualitative evaluation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive for amyloid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative for amyloid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test comparing the proportion of amyloid positive subjects between clinical diagnosis groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0253</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test comparing the proportion of amyloid positive subjects between clinical diagnosis groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test comparing the proportion of amyloid positive subjects between clinical diagnosis groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4184</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test comparing the proportion of amyloid positive subjects between clinical diagnosis groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Cortical to Cerebellum SUVR</title>
        <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
        <time_frame>50-60 min after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AD Subjects</title>
            <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
          </group>
          <group group_id="O2">
            <title>MCI Subjects</title>
            <description>MCI (mild cognitive impairment)
florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cortical to Cerebellum SUVR</title>
          <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
          <units>SUVR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.271" spread="0.182"/>
                    <measurement group_id="O2" value="1.112" spread="0.197"/>
                    <measurement group_id="O3" value="1.022" spread="0.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance P value testing for an overall difference in the mean cortical SUVR between the clinical diagnostic groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0039</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance contrast P value testing for difference in the mean cortical SUVR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0357</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance contrast P value testing for difference in the mean cortical SUVR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance contrast P value testing for difference in the mean cortical SUVR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2118</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AD Subjects</title>
          <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
        <group group_id="E2">
          <title>MCI Subjects</title>
          <description>MCI (mild cognitive impairment)
florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
        <group group_id="E3">
          <title>Healthy Controls</title>
          <description>florbetapir (18F) : IV injection, 370 MBq(10mCi), single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals, Inc.</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

